Ophthalmology Practice Valuation in 2026: What Your Practice Is Actually Worth

Whether you're planning to sell in 12 months or 12 years, understanding how your ophthalmology practice is valued creates decisions worth hundreds of thousands — sometimes millions — of dollars. The practices that receive the highest valuations in 2026 aren't necessarily the busiest or the most clinically distinguished. They're the most operationally excellent — and that distinction is something a consultant can measurably improve before you go to market.

How Ophthalmology Practices Are Valued in 2026

The dominant valuation methodology for ophthalmology practices in private equity and strategic buyer transactions is an EBITDA multiple — Earnings Before Interest, Taxes, Depreciation, and Amortization, multiplied by a market-determined factor.

Current 2026 EBITDA multiple ranges by practice type:

• General ophthalmology (single physician): 4x–5.5x EBITDA
• General ophthalmology (multi-physician group): 5x–7x EBITDA
• Cataract/refractive surgical focus: 6x–8x EBITDA
• Retina subspecialty practice: 7x–9x EBITDA
• Large multi-location groups: 8x–11x EBITDA (platform premium)

What Drives Premium Multiples

Within each category, there's significant multiple variation based on operational factors that directly affect a buyer's risk assessment and growth potential projection:

Clean, Documented Operations

Buyers apply a risk discount to practices with operational chaos — high staff turnover, inconsistent billing, patient satisfaction problems. A practice with documented SOPs, stable staff, and consistent KPI performance commands a premium multiple because the buyer can project future performance with confidence.

Revenue Quality and Diversification

Practices heavily dependent on a single revenue source (e.g., 80%+ from insurance-reimbursed exams) receive lower multiples than practices with diversified revenue — surgical fees, premium IOL upgrades, dry eye programs, optical dispensing. Revenue diversity reduces concentration risk and typically indicates higher revenue per patient.

Staff Independence from the Physician

The most common value destroyer in ophthalmology practice sales: practices where the physician is the practice — where patient relationships, referral relationships, and daily operations are so physician-dependent that the business has no standalone value. Buyers pay premium multiples for practices with strong operational teams, documented processes, and patient loyalty systems that don't require the selling physician's continued presence.

Growth Trajectory

A practice with 3 years of revenue growth commands a higher multiple than a flat or declining practice. Buyers pay for momentum. If your practice is planning a sale in 3–5 years, implementing growth initiatives now — dry eye programs, premium IOL optimization, a recall system — creates the growth trajectory that maximizes your multiple.

The Operational Investment That Pays at Exit

Every dollar of EBITDA improvement generates $5–$8 in enterprise value at current multiples. A practice that invests $50,000 in operational consulting over 12 months and generates $100,000 in EBITDA improvement has created $500,000–$800,000 in additional enterprise value. The ROI math on pre-sale operational optimization is one of the most compelling in all of practice management.

Understanding your practice's current valuation — and what operational changes would most efficiently increase it — is a strategic conversation worth having well before you're ready to sell. Diana Andre's practice strategy consulting includes practice valuation assessment and a prioritized roadmap to maximize enterprise value.